Abstract
Background Esophageal carcinoma (ESCA) is often diagnosed at the advanced stages, has a poor survival rate and overall is one of the deadliest cancers world-wide. Recent studies have elaborated the significance of non-coding RNAs like pseudogenes, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in cancer progression. In this study, we constructed a four-component competing endogenous RNA (ceRNA) network in ECSA and suggested an RNA with prognostic potential.
Materials and methods Expression profiles of mRNAs, pseudogenes, lncRNAs and miRNAs were collected from The Cancer Genome Atlas (TCGA) database. A ceRNA network was constructed based on differentially-expressed RNAs. KEGG and GO functional analysis and PPI network analysis was carried out on differentially-expressed (DE) RNAs of the ceRNA network. Survival analysis was carried out on a selection of RNAs with the highest degree centrality ranks to discover potential prognostic biomarkers.
Results A four-component ceRNA network with 529 nodes and 729 edges was constructed. The most significant GO biological process terms included signal transduction, cell adhesion and positive regulation of gene expression. The analysis of KEGG pathways showed that DEmRNAs were significantly enriched in pathways such as cytokine-cytokine receptor interaction and Cell cycle. Amongst the RNAs that were found to be associated with survival, SYT10 had the highest hazard ratio and thus, proved to be a potential prognostic biomarker for ESCA.
Conclusion Our study presented a four-component ceRNA network for ESCA, and identified RNA candidates that were associated with survival of ECSA. Further experimental evaluations and precise validation studies are needed for their clinical significances and roles in the progression of ESCA.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially supported by a grant from Isfahan University of Medical Sciences, Isfahan, Iran [grant number 3400942].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The results published or shown here are in whole or part based upon data generated by the TCGA Research Network (https://portal.gdc.cancer.gov/legacy-archive/search/f). Data are available upon request to the corresponding author.
